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antibody titers in the following schedules: last trimester
from mother, umbilical cord blood at birth, and children at
6, 12, 24, 36, and 48 months old.
Results: The recruitment started in June 2006. By Jan-
uary 2008, 201 longitudinal serum specimens collected from
mothers, neonates, and 6-month-old babies (one mother
delivered twins) have been measured with EV71 neutraliz-
ing antibody titers. The seropositive rates (percentage of
antibody titer ≥ 1:8) in mothers, neonates, and 6-month-
old babies were 61%(122/201), 46%(93/202), and 0%(0/202),
respectively. Geometric mean titers (95% conﬁdence inter-
vals) of serum EV71 antibody in mothers and neonates were
10.2 (8.7, 11.5) and 8.5 (7.4, 9.7), respectively.
Conclusions: In northern Taiwan, only 46% of neonates
have protective antibody against EV71 and these maternal
antibody titers have declined to undetectable level (<8) by
6 months of age. Historical data in the 1998 epidemic also
showed that infants under 1 year old had the highest risk
of severe EV71 infection. Therefore, development of EV71
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The global polio eradication program recommends the
use of massive vaccination campaigns with live vaccine
through National Immunization Days (NIDs) to displace the
wild virus from the community. Immunodeﬁcient patients
may be indirectly infected and become chronic excre-
tors and potential reservoirs of polioviruses, a concern for
the post eradication era. This prospective study aimed to
assess the risk of community-acquired infection of immun-
odeﬁcient patients following NIDs, the dynamics of viral
excretion and the genetic variation of excreted viruses.
Sixteen children with various primary immunodeﬁciencies,
who did not receive the vaccine during the campaign, were
investigated. Stool samples were collected weekly, shortly
after the NIDs, during at least three months and processed
for viral isolation. Isolates were characterized by three
intratypic differenciation methods and partial sequencing
of the VP1/2A region. Polioviruses were detected in 4 out
of 16 patients (serotype1 in 3 patients and serotype3 in one
patient). Sequencing revealed more than 99% homology with
homotypic Sabin strains suggesting recent infection. Dura-
tion of viral excretion ranged from 1 to 7 weeks. Nine out
of eleven isolates from the 3 polio1-infected patients dis-
closed a Non Sabin Like phenotype by ELISA and had recurent
mutations within or close to the neutralizing antigenic sites.
The risk of secondary infection in immunodeﬁcient patients
is within the range reported for the general population.
Although none of the four infected patients developed
prolonged viral excretion, particular viral variants were
selected and may be of epidemiological signiﬁcance.
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The increasing prevalence of inﬂuenza viruses resis-
tant to antiviral drugs such as amantadine and oseltamivir
undermines our ability to defend against future inﬂuenza
pandemics. There is an urgent need to develop novel
antiviral agents which are robust and offer broad-spectrum
protection against the ever changing inﬂuenza viruses. The
objective of this study is to evaluate the in vivo antivi-
ral efﬁcacy nucleic acid-based immunomodulators such as
Poly ICLC (synthetic ds RNA) and oligonucleotides con-
taining unmethylated CpG using a mouse lethal infection
model with inﬂuenza A/PR/8/34 (H1N1) and/or with the
highly pathogenic avian inﬂuenza H5N1 (HPAI) viruses.
Groups of BALB/c mice were pre-treated intranasally with
1 or 2 doses of liposome-encapsulated Poly ICLC (LE-Poly
ICLC, 20g/dose/mouse) or with CpG (5g/dose/mouse)
oligonucleotides. At various times post pre-treatment, the
animals were challenged intranasally with multiple doses of
inﬂuenza A/PR/8/34 or with HPAI viruses, and survival rates
of control and pre-treated mice were compared at day 14
post infection. Pre-treatment with liposome-encapsulated
Poly ICLC provided complete protection against 10 LD50
inﬂuenzaA/PR/8/34 and 1 LD50 dose of HPIA virus. When
the challenge dose of HPIA was increased to 4 LD50, the pro-
tection provided by LE-Poly ICLC was 63—75% (p < 0.001 vs
control), with all control mice succumbed to the infection.
Pre-treatment with CpG oligonucleotides provided complete
protection to mice against 5 LD50 inﬂuenza A/PR/8/34. The
window of protection (the time interval between drug pre-
treatment and virus challenge) was 21 days for LE-Poly ICLC
and 4 days for CpG oligonucleotides, respectively. RT-PCR
analyses of mouse lung tissues from LE-Poly ICLC treated
mice showed activation of toll-like receptor-3 pathway, and
induction of cytokines including IL 1-, -, IFN-, TNF-,
among others. Collectively, these results suggest that LE-
Poly ICLC can provide broad-spectrum protection and may
have an important role in protecting against avian or sea-
sonal inﬂuenza infections.
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